<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

        <ul class="navbar-nav ml-auto">
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="peak-registry.html">
                <img src="images/icons/peak-registry-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
          </ul>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div class="row">
          <div class="col-sm-9 col-7">
            <h1 class="mb-4"><img class="energize" src="images/energize-t.png"></h1>
          </div>

          <div class="col-sm-3 col-5">
            <span class="badge blue-dark float-right mt-1">STATUS: INITIATING IN 2021</span>
          </div>
        </div>
        <div class="row">
            <div class="col-md-8">
              <h4 class="font-weight-normal mb-3">A phase 3, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of mitapivat in subjects with transfusion-dependent α– or β– thalassemia</h4>

              <div class="block">
                <img src="images/phase-3-energize-t.png" class="mb-0" />
              </div>

              <div class="block p-0">
                <div class="row">
                  <div class="col-md-6 pr-0">
                    <div class="p-30">
                      <p class="mb-1"><strong>Key Inclusion Criteria</strong></p>
                      <ul class="mb-0 pl-20">
                          <li>≥18 years of age at the time of providing informed consent</li>
                          <li>Diagnosis of β-thalassemia with or without α-globin gene mutations, HbE/β-thalassemia, or α-thalassemia/HbH disease</li>
                          <li>Transfusion-dependent, defined as 6 to 20 RBC units transfused and a ≤6-week transfusion-free period during the 24-week period before randomization</li>
                      </ul>
                    </div>
                  </div>
                  <div class="col-md-6 pl-0 d-flex">
                    <div class="p-30 side-block-gray">
                      <p class="mb-1"><strong>Key Exclusion Criteria</strong></p>
                      <ul class="mb-0 pl-20">
                          <li>Pregnant or breastfeeding</li>
                          <li>Documented history of homozygous or heterozygous HbS or HbC</li>
                          <li>Certain prior or current therapies</li>
                          <li>Significant medical condition that confers an unacceptable risk to participating in the study and/or could confound the interpretation of the study data in the opinion of the investigator</li>
                      </ul>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div class="col-md-4">
              <div class="block side-block-container">
                <div class="side-block">
                  <p class="mb-1"><strong>Primary Endpoint</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Transfusion reduction response, defined as a ≥50% reduction in transfused RBC units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline</li>
                  </ul>
                </div>
                <div class="side-block side-block-gray">
                  <p class="mb-1"><strong>Key Secondary Endpoints</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with baseline</li>
                      <li>≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with baseline</li>
                      <li>≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with baseline</li>
                  </ul>
                </div>
              </div>
            </div>
        </div>
        <footer>
            <div class="row">
              <div class="col-md-7">
                <p class="text-left mb-4">BID = twice daily</p>
              </div>
              <div class="col-md-5">
                <p class="text-right">For full inclusion and exclusion criteria, as well as study locations, search ClinicalTrials.gov for (NCT04770779)<br/>
                  For more information (physician/HCP only),<br/> 
                please email medinfo@agios.com BID = twice daily<br/> 
              &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
              </div>
            </div>
        </footer>
      </div>
    </main>


    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
  </body>
</html>